Trump secures $550B pharma investment pledges in exchange for pricing exemptions

Major pharmaceutical firms including AbbVie, Pfizer, and Lilly have committed $550 billion in investments to lower prices, boost production, and fund R&D, in exchange for exemptions from pricing pressures. The deal marks a significant policy shift, trading regulatory relief for domestic investment commitments. Market impact hinges on whether these pledges translate into actual price reductions and production gains.